Bryolat

Bryolat is a nanoparticle-based therapy developed by Aphios International for the treatment of HIV-1 latency. It is designed to function as a latency-reversing agent (LRA) as part of a 'shock and kill' strategy aimed at achieving a functional cure for HIV. The drug utilizes bryostatin-1 (or a bryostatin analog), encapsulated in polymer nanospheres using Aphios's proprietary PNC (Polymer Nanospheres/Nanocapsules) technology. The mechanism of action involves the activation of Protein Kinase C (PKC), which induces the expression of latent HIV-1 proviruses in resting CD4+ T cells. This activation makes the infected cells visible to the immune system and susceptible to clearance by antiretroviral therapy or immune-mediated mechanisms. The nanoparticle formulation is intended to enhance the therapeutic index of the bryostatin compound by improving its stability, solubility, and targeted delivery while potentially reducing systemic toxicity.

Brand names

Bryolat